Arvind Remedies has entered into a Memorandum of Understanding (MoU) with Adesh University, Bhatinda, Punjab to transfer the patent right to undertake exclusive manufacturing, marketing and commercialisation of drugs for Type-II diabetes, depression, irritable bowel syndrome (IBS) and coronary heart disease. These drugs will be manufactured in the form of tablets and will be launched in the end of 2017, first in the domestic market which will be followed by the global market.
Dr B Arvind Shah, Managing Director and Chief Executive Officer, Arvind Remedies, said, “According to the International Diabetes Federation, 382 million people across world have diabetes, which is expected to rise to 592 million by 2035. The number of people with Type-II diabetes is increasing in every country. In order to curb this disease, we have come up with new drug that is from the botanical source which ensures zero side effects on the health of the patient. We are expecting this new drug to be available in the markets by mid 2015.”
| Product Pipeline |
|
He further added, “Coronary heart disease is also the most common type of heart disease and is killing more than 385,000 people annually. We are happy to share that, we have been successful in developing a new drug, which will help in treatment of coronary heart disease.”
The MoU was signed in the presence of Prof (Dr) G P Dubey, emeritus professor, inventor of these new drugs. The Vice Chancellor of Adesh University, Col Dr G PI Singh signed the MoU on behalf of Adesh University, while Dr B Arvind Shah, Managing Director and Chief Executive Officer signed the MoU on behalf of Arvind Remedies, Chennai.
EP News Bureau – Mumbai